Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SAR443820
RIPK1 inhibitor · 4 trials · 4 indications
Maximum plasma concentration
Area under the plasma concentration versus time curve from time zero to the real time last
Area under the plasma concentration versus time curve
| Arm | Type | Description |
|---|---|---|
| Part-A, Period-1 | EXPERIMENTAL | Single dose of SAR443820 tablet on Day 1 |
| Part-A, Period-2 | EXPERIMENTAL | Single dose of SAR443820 tablet on Day 6, and erythromycin ethyl succinate (EES) three-time a day (TID) from Day 1 to Day 9 |
| Part-B, Period-1 | EXPERIMENTAL | Single dose of SAR443820 capsule on Day 1 |
| Part-B, Period-2 | EXPERIMENTAL | Single dose of SAR443820 capsule on Day 6, and Itraconazole once daily (QD) from Day 1 to Day 11 |
| SAR443820 | EXPERIMENTAL | Participants will receive a single sequence of 3 different doses of SAR443820 in a total of 3 treatment periods |
| Treatment A | EXPERIMENTAL | Single dose of SAR443820 tablet in fasted condition |
| Treatment B | EXPERIMENTAL | Single dose of SAR443820 capsule in fasted condition |
| Treatment C | EXPERIMENTAL | Single dose of SAR443820 tablet in fasted condition |
| Treatment D | EXPERIMENTAL | Single dose of SAR443820 tablet in fed condition |
| Placebo | PLACEBO_COMPARATOR | Single dose oral ascending dose (part 1a) and multiple ascending oral dose (part 2) of matching placebo |
| Name | Type | Description |
|---|---|---|
| SAR443820 | DRUG | Tablet by oral administration |
| Erythromycin ethyl succinate | DRUG | Tablet by oral administration |
| Itraconazole | DRUG | Capsule by oral administration |
| RIPK1 inhibitor | DRUG | Capsule Oral |
| Placebo | DRUG | Matching Capsule / Oral |
Inclusion Criteria: * Part A: male or female participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent * Part B: male participant only must be 18 to 55 years of age inclusive, at the time of signing the informed consent * Body weight between 50.0 and 100.0 kg,...
RIPK1 inhibitor is an investigational small molecule being developed by Sanofi for use in multiple sclerosis. It is currently in Phase 1 clinical development, with a completed study in healthy subjects. The drug is not yet approved and remains in clinical trials.
RIPK1 inhibitor targets the RIPK1 protein, which is involved in inflammatory and cell death pathways. By inhibiting RIPK1, the drug aims to modulate these pathways, which are relevant to neurological conditions like multiple sclerosis. The exact mechanism is being evaluated in early-stage trials.
RIPK1 inhibitor is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi is conducting clinical trials to evaluate the drug's safety and tolerability in healthy subjects.
RIPK1 inhibitor is in Phase 1 clinical development. A Phase 1 study has been completed, and the drug is still investigational. It has not received regulatory approval and is not yet available for clinical use.
RIPK1 inhibitor has one completed Phase 1 trial, NCT04982991, which was a single ascending dose study in healthy adult Chinese and Japanese female and male participants. The study enrolled 14 participants in the United Kingdom and evaluated the drug in the context of multiple sclerosis.
Yes, RIPK1 inhibitor is also known as SAR443820. The completed Phase 1 trial NCT04982991 was titled 'Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants,' confirming the alternative name.